Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
16.69
+0.99 (6.31%)
At close: Nov 9, 2026, 4:00 PM EST
16.53
-0.16 (-0.96%)
After-hours: Nov 9, 2026, 5:20 PM EST
Scribe Therapeutics Revenue
Scribe Therapeutics had revenue of $1.92M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $33.30M. In the year 2025, Scribe Therapeutics had annual revenue of $51.17M with 86.68% growth. That makes Scribe Therapeutics the 30,709th largest company in the world by revenue and 4,047th in the United States.
Revenue (ttm)
$33.30M
Revenue Growth
+86.68%
P/S Ratio
9.54
Revenue / Employee
$406,122
Employees
82
Market Cap
315.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.17M | 23.76M | 86.68% |
| Dec 31, 2024 | 27.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
SCTX News
- 4 days ago - Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 5 days ago - Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 - GlobeNewsWire
- 6 weeks ago - Cathie Wood’s ARK Investment buys 143.3K shares of Scribe Therapeutics today - TheFly
- 2 months ago - Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72) - TheFly
- 2 months ago - Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Scribe Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Scribe Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Scribe Therapeutics Slides: Investor presentation - Filings